By Melane Sampson
Closely held Imviva Biotech is advancing a next-generation approach to cell therapy designed to overcome some of the most persistent barriers facing allogeneic CAR-T development. By combining proprietary gene editing with sophisticated immune-evasion technology, the company aims to deliver off-the-shelf CAR-T therapies that match the power of autologous treatments—without the cost, delays, and manufacturing constraints that limit patient access today.
“We are a clinical-stage biotechnology company that is focused on engineering living medicines from healthy donor cells. Our approach is designed to deliver durable, safe, effective allogeneic cell treatments for cancers and immune diseases with high unmet needs,” Jan Davidson-Moncada, MD, PhD, CMO of Imviva, says in an interview with BioTuesdays.
Backed by top-tier investors, the company has raised more than $170 million to date and has already dosed more than 300 patients across programs in China, providing a substantial clinical foundation as it advances global development.
Dr. Davidson-Moncada explains that autologous CAR-T therapies—made from the patient’s own T cells—have transformed the treatment landscape for several blood cancers but come with well-known limitations. For example, manufacturing can take weeks, costs can exceed $400,000 per patient, and many patients with advanced cancer or autoimmune disease simply don’t have enough healthy T cells to manufacture a product. For patients with rapidly progressing disease, these manufacturing delays can be particularly problematic—some patients’ conditions deteriorate significantly during production, potentially making them ineligible for treatment by the time their CAR-T cells are ready.
“Allogeneic CAR-T cells come from healthy donors, which means immediate availability and consistent product quality,” he says. “That opens the door to treating patients who otherwise wouldn’t have access.”
However, Dr. Davidson-Moncada points out that allogeneic approaches introduce their own challenges. Because donor cells are foreign to the patient’s immune system, they are at risk of being rejected—or worse, causing graft-versus-host disease (GvHD). Many allogeneic programs rely on intensive lymphodepleting chemotherapy to suppress the patient’s immune response, increasing toxicity and limiting broader use.
“Our strategy is designed to capture the advantages of allogeneic CAR-T while minimizing these drawbacks,” he contends.
Central to Imviva’s approach is its proprietary ANSWER technology—short for Antibody SWitch Engineered Receptor. Rather than broadly disabling the patient’s immune system, ANSWER enables CAR-T cells to selectively evade immune attack while remaining active against disease.
“What we do is embed inhibitory ligands into the CAR-T cell,” Dr. Davidson-Moncada explains. “This dampens the immune reaction of the host toward the CAR-T cell without eliminating the immune system altogether.”
He adds that, in practical terms, this means the patient retains the ability to fight infections, while the engineered CAR-T cells persist and expand long enough to do their job. Importantly, the ANSWER construct also contains activating signals that enhance CAR-T performance.
“The interaction actually potentiates the CAR-T cell, and we see better expansion and persistence, which is exactly what you want in patients.”
Through multiple design iterations of its ANSWER technology—now in its fifth generation—Imviva has been able to reduce the intensity of lymphodepleting chemotherapy to levels comparable with autologous CAR-T, improving safety without sacrificing efficacy. A critical component of Imviva’s strategy is manufacturing scalability. The company’s process generates 80 to 160 patient doses per donor apheresis, with consistency validated across 300+ treated patients in its China trials—demonstrating the standardization required for true off-the-shelf delivery.
A breakthrough opportunity in T-cell malignancies, one of Imviva’s most advanced programs is CTD402, a CD7 surface protein-targeted allogeneic CAR-T therapy being developed for relapsed or refractory T-cell malignancies, including T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma (T-ALL/LBL).
“T-cell cancers are uniquely challenging,” Dr. Davidson-Moncada says. “You can’t reliably harvest healthy T cells from patients because the cells themselves are malignant or damaged.”
He emphasizes that targeting T-cells also introduces a phenomenon known as fratricide—where CAR-T cells attack each other because they share the same surface marker. CTD402 addresses this by knocking out the CD7 target on the CAR-T cells themselves, preventing self-destruction. Additional edits eliminate the T-cell receptor to prevent GvHD, and the ANSWER platform protects against immune rejection.
“Overall, we’re harnessing the benefits of both autologous and allogeneic approaches while removing the key limitations of donor-derived cells,” Dr. Davidson-Moncada asserts.
Clinically, CTD402 has shown encouraging safety and efficacy across multiple studies in China, with durable remissions and manageable toxicity using standard lymphodepletion. The program received FDA clearance for a global Phase 1b/2 trial in 2025 and has been granted Rare Pediatric Disease Designation, Regenerative Medicine Advanced Therapy designation and Orphan Drug Designation.
“This is a very high unmet-need disease,” Dr. Davidson-Moncada clarifies. “Patients with refractory or relapsed T-ALL/LBL are actively seeking clinical trials because there are so few standard-of-care options—particularly for children and young adults, who make up much of the patient population for this disease.”
While CTD402 targets aggressive cancers, CTA313 represents Imviva’s push into autoimmune disease—a rapidly emerging frontier for CAR-T therapy.
Dr. Davidson-Moncada highlights that CTA313 is a dual-targeting CAR-T therapy directed against the protein marker CD19 and B-cell maturation antigen (BCMA), designed to eliminate disease-driving B cells and potentially reset the immune system. The product incorporates multiple genetic edits to prevent GvHD and immune rejection, alongside ANSWER technology for persistence and safety.
“In autoimmune disease, our goal is to achieve deep, durable responses without ongoing immunosuppression,” he says.
Beyond ANSWER, another differentiating feature of CTA313 is its resistance to a commonly used immunosuppressive drug. This strategic design allows clinicians to transiently suppress the patient’s immune system to support CAR-T expansion—without relying on intensive chemotherapy.
“We believe this gives us four key advantages, including improved CAR-T persistence, reduced lymphodepletion, mitigation of immune-related side effects, and smoother withdrawal from chronic immunosuppressive therapies,” Dr. Davidson-Moncada says.
In China, CTA313 has been tested across multiple autoimmune indications, including systemic lupus erythematosus and lupus nephritis. Early results show a mild safety profile with striking immunological findings: the therapy deeply depletes disease-driving B cells, which are subsequently replaced by healthy, naïve B cells. Critically, this process eliminates auto-reactive antibodies and achieves what the team calls ‘immune reset’—evidence of fundamental immune system restoration—leading to durable remissions.
“The patients actually do really well,” Dr. Davidson-Moncada says. “We’re seeing strong remission rates with no significant toxicity.”
The company is leveraging data from its clinical experiences in China to accelerate global development—a key strategic advantage, he indicates. “We’re clearly at an advantage having early clinical experience, through a quick iterative process—tested in patients, made changes, and then gone back to test again—allowing us to refine the product, improve patient outcomes and de-risk global development.”
This iterative approach has informed everything from lymphodepletion dosing to construct design, enabling Imviva to advance programs with greater confidence as the company enters the U.S. and global trials, he adds.
In addition to CTD402 and CTA313, Imviva’s broader platform includes CTA311, a CD-19-targeted allogeneic CAR-T therapy, as well as earlier-stage programs in multiple myeloma and acute myeloid leukemia. Together, these assets highlight the extensibility of the ANSWER platform across oncology and autoimmune indications.
Going forward, Dr. Davidson-Moncada says the company is very encouraged by the successes of its two advanced clinical programs, a differentiated immune-evasion strategy, and a clear regulatory and development path.
“Our mission is to bring groundbreaking allogeneic CAR-T cell therapies to patients who really need them,” he concludes. “We believe we’re building the foundation for safer, more effective, off-the-shelf cell therapies that can reach patients worldwide.”
• • • • •
To connect with Imviva Biotech or any other companies featured on BioTuesdays, send us an email at editor@biotuesdays.com.
